Shinil Pharmaceutical신일제약
012790 · KOSDAQ · ₩012790 · 신일제약
₩6,340▲ ₩20 (0.32%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 42.6% | 41.5% | 45.5% | 42.1% | 44.6% | 39.6% |
| Operating margin | 6.7% | 9.2% | 17.0% | 15.7% | 17.1% | 12.9% |
| Net margin | 5.7% | 9.3% | 16.0% | 15.3% | 15.2% | 10.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.8% | −9.9% | +0.3% | +11.4% | +29.6% | — |
| Operating income growth | −21.0% | −51.5% | +8.8% | +2.5% | +71.1% | — |
| Net income growth | −33.8% | −47.3% | +4.8% | +12.2% | +82.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 3.3% | 5.0% | 10.2% | 10.6% | 10.3% | 5.9% |
| Return on assets | 2.9% | 4.5% | 9.0% | 9.2% | 8.9% | 5.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 13.9% | 11.2% | 13.2% | 13.0% | 15.9% | 13.9% |
| Net debt to equity | −25.8% | — | — | — | — | — |
| Current ratio | 488.7% | 562.9% | 470.7% | 486.3% | 421.6% | 486.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Shinil Pharmaceutical / 신일제약 / 012790 / KRX:012790
Source: KRX statistical information